229 related articles for article (PubMed ID: 30486290)
21. Anti-tumor compound RY10-4 suppresses multidrug resistance in MCF-7/ADR cells by inhibiting PI3K/Akt/NF-κB signaling.
Yang X; Ding Y; Xiao M; Liu X; Ruan J; Xue P
Chem Biol Interact; 2017 Dec; 278():22-31. PubMed ID: 28987325
[TBL] [Abstract][Full Text] [Related]
22. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
23. miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A.
Zhu X; Li H; Long L; Hui L; Chen H; Wang X; Shen H; Xu W
Acta Biochim Biophys Sin (Shanghai); 2012 Jun; 44(6):519-26. PubMed ID: 22510476
[TBL] [Abstract][Full Text] [Related]
24. A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells.
Xiong F; Jiang M; Huang Z; Chen M; Chen K; Zhou J; Yin L; Tang Y; Wang M; Ye L; Zhan Z; Duan J; Fu H; Zhang X
Integr Cancer Ther; 2014 Mar; 13(2):152-60. PubMed ID: 24105357
[TBL] [Abstract][Full Text] [Related]
25. Nobiletin potentiates paclitaxel anticancer efficacy in A549/T xenograft model: Pharmacokinetic and pharmacological study.
Feng SL; Tian Y; Huo S; Qu B; Liu RM; Xu P; Li YZ; Xie Y
Phytomedicine; 2020 Feb; 67():153141. PubMed ID: 31884406
[TBL] [Abstract][Full Text] [Related]
26. Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells.
Zhang Y; Bao C; Mu Q; Chen J; Wang J; Mi Y; Sayari AJ; Chen Y; Guo M
Neoplasma; 2016; 63(3):362-70. PubMed ID: 26925782
[TBL] [Abstract][Full Text] [Related]
27. Doxorubicin induces expression of multidrug resistance-associated protein 1 in human small cell lung cancer cell lines by the c-jun N-terminal kinase pathway.
Shinoda C; Maruyama M; Fujishita T; Dohkan J; Oda H; Shinoda K; Yamada T; Miyabayashi K; Hayashi R; Kawagishi Y; Fujita T; Matsui S; Sugiyama E; Muraguchi A; Kobayashi M
Int J Cancer; 2005 Oct; 117(1):21-31. PubMed ID: 15880572
[TBL] [Abstract][Full Text] [Related]
28. Nobiletin inhibits epithelial-mesenchymal transition of human non-small cell lung cancer cells by antagonizing the TGF-β1/Smad3 signaling pathway.
Da C; Liu Y; Zhan Y; Liu K; Wang R
Oncol Rep; 2016 May; 35(5):2767-74. PubMed ID: 26986176
[TBL] [Abstract][Full Text] [Related]
29. Acacetin enhances the therapeutic efficacy of doxorubicin in non-small-cell lung carcinoma cells.
Punia R; Raina K; Agarwal R; Singh RP
PLoS One; 2017; 12(8):e0182870. PubMed ID: 28859099
[TBL] [Abstract][Full Text] [Related]
30. Visfatin mediates doxorubicin resistance in human non-small-cell lung cancer via Akt-mediated up-regulation of ABCC1.
Cao Z; Liang N; Yang H; Li S
Cell Prolif; 2017 Oct; 50(5):. PubMed ID: 28762597
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers.
Chen YL; Yang TY; Chen KC; Wu CL; Hsu SL; Hsueh CM
Cell Oncol (Dordr); 2016 Oct; 39(5):411-433. PubMed ID: 27306525
[TBL] [Abstract][Full Text] [Related]
32. Curcumin inhibits the growth via Wnt/β-catenin pathway in non-small-cell lung cancer cells.
Wang JY; Wang X; Wang XJ; Zheng BZ; Wang Y; Wang X; Liang B
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(21):7492-7499. PubMed ID: 30468498
[TBL] [Abstract][Full Text] [Related]
33. Knockdown of CABYR-a/b increases chemosensitivity of human non-small cell lung cancer cells through inactivation of Akt.
Qian Z; Li M; Wang R; Xiao Q; Wang J; Li M; He D; Xiao X
Mol Cancer Res; 2014 Mar; 12(3):335-47. PubMed ID: 24362251
[TBL] [Abstract][Full Text] [Related]
34. Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1.
Chen J; Lan T; Hou J; Zhang J; An Y; Tie L; Pan Y; Liu J; Li X
Int J Biochem Cell Biol; 2012 May; 44(5):759-69. PubMed ID: 22305890
[TBL] [Abstract][Full Text] [Related]
35. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
[TBL] [Abstract][Full Text] [Related]
36. Delicaflavone induces autophagic cell death in lung cancer via Akt/mTOR/p70S6K signaling pathway.
Sui Y; Yao H; Li S; Jin L; Shi P; Li Z; Wang G; Lin S; Wu Y; Li Y; Huang L; Liu Q; Lin X
J Mol Med (Berl); 2017 Mar; 95(3):311-322. PubMed ID: 27838742
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of disheveled-2 resensitizes cisplatin-resistant lung cancer cells through down-regulating Wnt/β-catenin signaling.
Luo K; Gu X; Liu J; Zeng G; Peng L; Huang H; Jiang M; Yang P; Li M; Yang Y; Wang Y; Peng Q; Zhu L; Zhang K
Exp Cell Res; 2016 Sep; 347(1):105-113. PubMed ID: 27432651
[TBL] [Abstract][Full Text] [Related]
38. DLJ14, a novel chemo-sensitization agent, enhances therapeutic effects of adriamycin against MCF-7/A cells both in vitro and in vivo.
Zhang P; Zheng BB; Wang HY; Chen JH; Liu XY; Guo XL
J Pharm Pharmacol; 2014 Mar; 66(3):398-407. PubMed ID: 24533823
[TBL] [Abstract][Full Text] [Related]
39. Tanshinone IIA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way.
Xie J; Liu JH; Liu H; Liao XZ; Chen Y; Lin MG; Gu YY; Liu TL; Wang DM; Ge H; Mo SL
BMC Cancer; 2016 Nov; 16(1):899. PubMed ID: 27863471
[TBL] [Abstract][Full Text] [Related]
40. [Modulation of human small cell lung cancer cell line GLC4/ADR multidrug resistance in the inhibition of multidrug resistance-associated protein and its antisense].
Peng X; Feng F; Zhang W
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):355-8. PubMed ID: 11810759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
